Nektar's Sole Skeptic Warns of Parallels to Biggest Biotech Flop

(Bloomberg) -- A long-time skeptic of Nektar Therapeutics on Wall Street remains cautious after Monday’s 42 percent plunge, the worst performance for an S&P 500 Index member in more than five years.
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.